Movement Alert｜RemeGen Falls 5.27% in Regular Trading, Massive Restricted Share Unlock Triggers Profit-Taking After Prior Session Surge

Market Focus06-30 10:35

On June 30, RemeGen (09995.HK) fell 5.27% in regular trading, trading at HKD 75.5 per share, with turnover of HKD 292 million.

On the news front, 192.8 million IPO restricted shares — representing 34.16% of total share capital and corresponding to an unlock value of approximately RMB 21.79 billion — are scheduled to begin trading on July 1, making it the second-largest single-stock unlock on A-shares for the week. The massive unlock comes one day after the stock surged over 16% on June 29, driven by positive clinical data for its ADC drug Disitamab Vedotin and broader sector tailwinds from innovative drug commercialization momentum. The combination of impending supply overhang and profit-taking from the prior session rally pressured shares.

Notably, the company disclosed that because cash dividends have not met regulatory thresholds under Shanghai Stock Exchange self-regulatory guidelines, the unlocking shareholders are prohibited from reducing holdings via centralized bidding or block trades, meaning actual selling pressure remains substantially lower than headline figures suggest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160407714?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160407714","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Falls 5.27% in Regular Trading, Massive Restricted Share Unlock Triggers Profit-Taking After Prior Session Surge","media":"Market Focus","content":"<p><p>On June 30, RemeGen (09995.HK) fell 5.27% in regular trading, trading at HKD 75.5 per share, with turnover of HKD 292 million.</p><p>On the news front, 192.8 million IPO restricted shares — representing 34.16% of total share capital and corresponding to an unlock value of approximately RMB 21.79 billion — are scheduled to begin trading on July 1, making it the second-largest single-stock unlock on A-shares for the week. The massive unlock comes one day after the stock surged over 16% on June 29, driven by positive clinical data for its ADC drug Disitamab Vedotin and broader sector tailwinds from innovative drug commercialization momentum. The combination of impending supply overhang and profit-taking from the prior session rally pressured shares.</p><p>Notably, the company disclosed that because cash dividends have not met regulatory thresholds under Shanghai Stock Exchange self-regulatory guidelines, the unlocking shareholders are prohibited from reducing holdings via centralized bidding or block trades, meaning actual selling pressure remains substantially lower than headline figures suggest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Falls 5.27% in Regular Trading, Massive Restricted Share Unlock Triggers Profit-Taking After Prior Session Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Falls 5.27% in Regular Trading, Massive Restricted Share Unlock Triggers Profit-Taking After Prior Session Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-30 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 30, RemeGen (09995.HK) fell 5.27% in regular trading, trading at HKD 75.5 per share, with turnover of HKD 292 million.</p><p>On the news front, 192.8 million IPO restricted shares — representing 34.16% of total share capital and corresponding to an unlock value of approximately RMB 21.79 billion — are scheduled to begin trading on July 1, making it the second-largest single-stock unlock on A-shares for the week. The massive unlock comes one day after the stock surged over 16% on June 29, driven by positive clinical data for its ADC drug Disitamab Vedotin and broader sector tailwinds from innovative drug commercialization momentum. The combination of impending supply overhang and profit-taking from the prior session rally pressured shares.</p><p>Notably, the company disclosed that because cash dividends have not met regulatory thresholds under Shanghai Stock Exchange self-regulatory guidelines, the unlocking shareholders are prohibited from reducing holdings via centralized bidding or block trades, meaning actual selling pressure remains substantially lower than headline figures suggest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1160407714","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160407714","pubTimestamp":1782786946,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 30, RemeGen (09995.HK) fell 5.27% in regular trading, trading at HKD 75.5 per share, with turnover of HKD 292 million.On the news front, 192.8 million IPO restricted shares — representing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"异动提示|RemeGen常规交易跌5.27%，前一交易日大涨后大规模限售股解锁引发获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On June 30, RemeGen (09995.HK) fell 5.27% in regular trading, trading at HKD 75.5 per share, with turnover of HKD 292 million.On the news front, 192.8 million IPO restricted shares — representing 34.16% of total share capital and corresponding to an unlock value of approximately RMB 21.79 billion — are scheduled to begin trading on July 1, making it the second-largest single-stock unlock on A-shares for the week. The massive unlock comes one day after the stock surged over 16% on June 29, driven by positive clinical data for its ADC drug Disitamab Vedotin and broader sector tailwinds from innovative drug commercialization momentum. The combination of impending supply overhang and profit-taking from the prior session rally pressured shares.Notably, the company disclosed that because cash dividends have not met regulatory thresholds under Shanghai Stock Exchange self-regulatory guidelines, the unlocking shareholders are prohibited from reducing holdings via centralized bidding or block trades, meaning actual selling pressure remains substantially lower than headline figures suggest.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160407714","isCrawlerRequest":true}